A Prospective, Multi-centre, Double-blind, Randomized Trial of Saroglitazar 4 mg versus Placebo in Patients With Alcoholic Liver Disease.
Latest Information Update: 16 Jun 2020
At a glance
- Drugs Saroglitazar (Primary)
- Indications Alcoholic liver disorders
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
Most Recent Events
- 19 May 2020 Status changed from recruiting to discontinued.
- 31 Jan 2020 New trial record